Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

The stock rallies as C3.ai touts enterprise AI momentum, but rising pressure from rivals puts its niche to the test.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

The all-new LG C5 OLED TV was released in March of this year, and Amazon just dropped the 55-inch model to $1,396.99 - a new ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...